drugset
drugset / Trial / NCT02227030

Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects

NCT02227030 ↗

Phase 1 Completed 71 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Safety and pharmacokinetics after oral single rising doses of BIIB 722 CL

Timeline

Start
2000-04
Primary completion
2000-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB 722 CL Unknown 10 mg Oral
Subject BIIB 722 CL Unknown 20 mg Oral
Subject BIIB 722 CL Unknown 50 mg Oral
Subject BIIB 722 CL Unknown 100 mg Oral
Subject BIIB 722 CL Unknown 200 mg Oral
Subject BIIB 722 CL Unknown 300 mg Oral
Subject BIIB 722 CL Unknown 450 mg Oral
Subject BIIB 722 CL Unknown 600 mg Oral
Subject BIIB 722 CL Unknown 750 mg Oral

Indications

No indication recorded.